VivoSeq
Cardiovascular

Cardiac Transplant

18

Pipeline Programs↗

3

Active Trials↗

12

Companies Involved↗

Cardiac Transplant is an emerging landscape with 18 programs across 12 companies. The most active players are Johnson & Johnson, Veloxis Pharmaceuticals, Prism Pharmaceuticals. 5 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

45/100

Pipeline Velocity

0/100

Mech. Concentration

21/100

Completion Rate

73/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 2V

Veloxis Pharmaceuticals

1 program

Phase 2P

Prism Pharmaceuticals

1 program

Phase 2Amgen logo

Amgen

1 program

Phase 2Sanofi logo

Sanofi

1 program

Phase 2Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

65%

Small molecule

13 of 20 classified programs — the dominant modality here.

35%ALL OTHERSMonoclonal antibody630%Protein / enzyme15%

Small molecule leads; the ring shows all 20 classified programs, each share of the total. Modality classified for 100% of 20 pipeline programs.

Analysis

Trial Status

15

clinical trials

Completed8 · 53%
Recruiting2 · 13%
Terminated2 · 13%
Enrolling by invitation1 · 7%
Withdrawn1 · 7%
Unknown status1 · 7%

Clinical Trials

Trial Activity

15 trials

Pilot Study: Interest of Belatacept as a Non-nephrotoxic Immunosuppressive Treatment in Cardiac Transplant Patients at Risk of Chronic Renal Failure (BELACOEUR)
Recruiting·NNantes University Hospital·Phase 2·NCT04180085·25 enrolled
Outcome Reflection for Immune Mediated Rejection by Utilizing Artificial Intelligence in Cardiac Transplant Patients Through Early and Late Echocardiographic Analysis (ORACLE)
Recruiting·MMayo Clinic·N/A·NCT06178744·500 enrolled
The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients
Enrolling by invitation·—·Phase 2·NCT03292861·60 enrolled
The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation
Completed·—·Phase 3·NCT02013037·36 enrolled
Intravenous Iron Supplement for Iron Deficiency in Cardiac Transplant Recipients
Completed·OOslo University Hospital·Phase 2/3·NCT03662789·102 enrolled
Tocilizumab in Cardiac Transplantation
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT03644667·385 enrolled
Renal Safety of Everolimus in Addition to Cyclosporine Microemulsion in Cardiac Transplant Recipients.
Completed·Novartis logoNovartis·Phase 3·NCT00170794
A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation
Completed·Roche logoRoche·Phase 4·NCT00048165·434 enrolled
Impact of Evolocumab in Cardiac Transplant Patients With CAV
Completed·UUniversity of Nebraska·Phase 2·NCT03944577·26 enrolled
EXCELLENT (EXpanded CELL ENdocardiac Transplantation)
Completed·CCellProthera·Phase 2·NCT02669810·49 enrolled
Safety/Efficacy of Everolimus and Neoral® in Adult Cardiac Transplant Patients With Established Allograft Vasculopathy
Completed·Novartis logoNovartis·Phase 3·NCT00097968
Clinical Pharmacology of Aliskiren in Combination With Cyclosporine in Cardiac Transplantation
Terminated·UUniversity of Colorado, Denver·Phase 4·NCT01235910·1 enrolled
Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation
Terminated·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT01278745·362 enrolled
Preemptive Zepatier Treatment in Donor HCV Positive to Recipient HCV Negative Cardiac Transplant
Withdrawn·RRaymond T. Chung, MD·Phase 4·NCT03026023
LOW CYCLO: Study Evaluating the Benefit of Two Doses of Ciclosporine in de Novo Cardiac Transplant
Unknown status·HHospices Civils de Lyon·Phase 4·NCT00159159·106 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)